What's in Prairie Eye Center's pipeline?

Prairie Eye Center has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Prairie Eye Center's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/prairie-eye-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Prairie Eye Center — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prairie Eye Center pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cosopt PF 2%-0.5% Ophthalmic Solution	Cosopt PF 2%-0.5% Ophthalmic Solution	marketed	Fixed-dose combination of carbonic anhydrase inhibitor and beta-blocker	Carbonic anhydrase II (dorzolamide component); beta-adrenergic receptors (timolol component)	Ophthalmology
Simbrinza 0.2%-1% Ophthalmic Suspension	Simbrinza 0.2%-1% Ophthalmic Suspension	marketed	Fixed-dose combination of carbonic anhydrase inhibitor and alpha-2 adrenergic agonist	Carbonic anhydrase II; alpha-2 adrenergic receptor	Ophthalmology

Therapeutic area mix

Ophthalmology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Prairie Eye Center:

Cite this brief

Drug Landscape (2026). Prairie Eye Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/prairie-eye-center. Accessed 2026-05-16.